Status:
COMPLETED
Post-marketing Safety Surveillance of Compound Kuh-seng Injection: a Registry Study
Lead Sponsor:
Zhong Wang
Collaborating Sponsors:
Shanxi Zhendong pharmaceutical Co. LTD.
Conditions:
Safety Surveillance
Adverse Drug Events
Eligibility:
All Genders
Brief Summary
This registry aims to monitor the safety of Compound Kuh-seng Injection and to identify the potential risk factors for the adverse drug reactions. Compound Kuh-seng Injection is a kind of natural comp...
Eligibility Criteria
Inclusion
- Patients who use Compound Kushen Injection in the monitoring hospitals
Exclusion
- None
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2018
Estimated Enrollment :
30283 Patients enrolled
Trial Details
Trial ID
NCT02239237
Start Date
September 1 2014
End Date
October 1 2018
Last Update
October 10 2018
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
HanDan Central Hospital
Handan, Hebei, China, 056001
2
Handan First Hospital
Handan, Hebei, China, 056002
3
Bai Qiu'en International Peace Hospital
Shijiazhuang, Hebei, China, 050082
4
Henan University Huaihe Hospital
Kaifeng, Henan, China, 475001